Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22423073 | 0.90 | PDE2A (0.52) | PDE2ACDK4CCND1TYMS | |
| SCHEMBL18282988 | 0.78 | PDE2A (0.78) | PDE2A | |
| SCHEMBL18283211 | 0.78 | PDE2A (0.78) | PDE2A | |
| SCHEMBL18283100 | 0.77 | PDE2A (0.62) | PDE2A | |
| SCHEMBL18283047 | 0.77 | PDE2A (0.62) | PDE2A | |
| SCHEMBL18282976 | 0.77 | PDE2A (0.65) | PDE2A | |
| SCHEMBL18283050 | 0.77 | PDE2A (0.62) | PDE2A | |
| SCHEMBL18282973 | 0.77 | PDE2A (0.65) | PDE2A | |
| SCHEMBL18283175 | 0.77 | PDE2A (0.65) | PDE2A | |
| SCHEMBL18283132 | 0.76 | PDE2A (0.51) | PDE2ACDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | PDE2A 2/4885CDK4 1789/4885CCND1 1630/4885 |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | PDE2A 2/4885CDK4 1789/4885CCND1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.